MLICM
HRMY icon

Metropolitan Life Insurance Company (MetLife)’s Harmony Biosciences HRMY Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,735
Closed -$58.3K – 972
2024
Q1 		$58.3K Sell
1,735
-295
-15% -$9.47K ﹤0.01% 1327
2023
Q4 		$65.6K Hold
2,030
– – ﹤0.01% 1304
2023
Q3 		$66.5K Buy
2,030
+212
+12% +$7.36K ﹤0.01% 1240
2023
Q2 		$64K Buy
1,818
+317
+21% +$10.9K ﹤0.01% 1280
2023
Q1 		$49K Sell
1,501
-120
-7% -$5.46K ﹤0.01% 1406
2022
Q4 		$89.3K Hold
1,621
– – ﹤0.01% 1116
2022
Q3 		$71.8K Hold
1,621
– – ﹤0.01% 1217
2022
Q2 		$79.1K Buy
1,621
+205
+14% +$9.23K ﹤0.01% 1206
2022
Q1 		$68.9K Sell
1,416
-4,631
-77% -$189K ﹤0.01% 1413
2021
Q4 		$258K Sell
6,047
-1,102
-15% -$43.9K ﹤0.01% 1841
2021
Q3 		$274K Hold
7,149
– – ﹤0.01% 1844
2021
Q2 		$202K Buy
+7,149
New +$214K ﹤0.01% 2132

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s HRMY Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Harmony Biosciences (HRMY) in Q2 2024, closing a stake of 1,735 shares — an estimated $58.3K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in HRMY in Q2 2021 and held it in 12 quarters. The position peaked at $274K in Q3 2021. 219 funds tracked by Wall St. Rank hold HRMY as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Harmony Biosciences position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,735 Harmony Biosciences shares in Q2 2024, an estimated $58.3K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Harmony Biosciences in Q2 2021 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Harmony Biosciences position peaked at $274K in Q3 2021.
  • 219 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.